Year: 2025

Thynk Health Appoints Matt Rockhold as Chief Commercial Officer to Accelerate AI-Driven Cancer Detection Across U.S. Health Systems

LEXINGTON, Ky., Sept. 22, 2025 /PRNewswire/ -- Thynk Health, a leading innovator in AI-powered diagnostic platforms, today announced the appointment...

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with...

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER,...

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...

error: Content is protected !!